dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Wen, Patrick Yung |
dc.contributor.author | Rodon Ahnert, Jordi |
dc.contributor.author | Mason, Warren |
dc.contributor.author | Beck, Joseph T |
dc.contributor.author | DeGroot, John |
dc.contributor.author | Donnet, Valerie |
dc.date.accessioned | 2021-10-20T08:06:20Z |
dc.date.available | 2021-10-20T08:06:20Z |
dc.date.issued | 2020-07 |
dc.identifier.citation | Wen PY, Rodon JA, Mason W, Beck JT, DeGroot J, Donnet V, et al. Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma. ESMO Open. 2020 Jul;5(4):e000673. |
dc.identifier.issn | 2059-7029 |
dc.identifier.uri | https://hdl.handle.net/11351/6422 |
dc.description | BKM120; Buparlisib; Glioblastoma |
dc.description.sponsorship | The study was initiated, funded and sponsored by Novartis Pharmaceuticals Corporation. The study was designed by the investigators and the sponsor. Design and conduct of the study was undertaken by the sponsor in collaboration with investigators. The study investigators and their respective research teams collected the data; Novartis Pharmaceuticals Corporation compiled the data for summation and analysis. All authors were responsible for data interpretation. Professor Wen prepared the article in conjunction with all the authors, including employees of the sponsor. The corresponding author had final responsibility for the decision to submit the manuscript for publication. |
dc.language.iso | eng |
dc.publisher | BMJ |
dc.relation.ispartofseries | ESMO Open;5(4) |
dc.rights | Attribution-NonCommercial 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ |
dc.source | Scientia |
dc.subject | Glioblastoma multiforme - Quimioteràpia |
dc.subject.mesh | Glioblastoma |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols |
dc.title | Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1136/esmoopen-2020-000673 |
dc.subject.decs | glioblastoma |
dc.subject.decs | protocolos de quimioterapia antineoplásica combinada |
dc.relation.publishversion | https://doi.org/10.1136/esmoopen-2020-000673 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Wen PY] Neuro-oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA. [Rodon JA] Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Mason W] Radiation-Oncology, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada. [Beck JT] Highlands Oncology Group, Fayetteville, Arkansas, USA. [DeGroot J] Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. [Donnet V] Novartis Pharma SAS, Paris, France |
dc.identifier.pmid | 32661186 |
dc.identifier.wos | 000554463200003 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |